NCT03692338View on ClinicalTrials.gov

INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions
Metastatic Renal Cell Carcinoma
Interventions
BEHAVIORAL

Exercise

Patients will be asked to complete 3 x 30 minute exercise sessions each week.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Duke University

OTHER

NCT03692338 - INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma | Biotech Hunter | Biotech Hunter